Cargando…
The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC
Previous studies have shown that oral administration of the NMDAR modulator NYX-2925 alleviates pain in several animal models of neuropathic pain and this appears to be through mPFC, but not spinal, mediated mechanisms. While much is known about the impact of neuropathic pain on NMDAR-mediated signa...
Autores principales: | Morrison, Gladys, Asiedu, Marina N., Priebe, Jessica M., Dunning, Jacqueline, Ghoreishi-Haack, Nayereh, Kroes, Roger A., Bowers, M. Scott, Barth, Amanda L., Cearley, Cassia N., Moskal, Joseph R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938954/ https://www.ncbi.nlm.nih.gov/pubmed/31909296 http://dx.doi.org/10.1016/j.ynpai.2019.100039 |
Ejemplares similares
-
NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
por: Khan, M Amin, et al.
Publicado: (2017) -
NYX‐2925 induces metabotropic N‐methyl‐d‐aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor
por: Bowers, M. Scott, et al.
Publicado: (2019) -
Dysfunction of the NAc-mPFC circuit in insomnia disorder
por: Shao, Ziqiang, et al.
Publicado: (2020) -
NYX‐2925, A Novel N‐methyl‐D‐aspartate Receptor Modulator: A First‐in‐Human, Randomized, Double‐blind Study of Safety and Pharmacokinetics in Adults
por: Houck, David R., et al.
Publicado: (2018) -
Amygdala GABA Neurons Project To vlPAG And mPFC
por: Sun, Ying, et al.
Publicado: (2019)